Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer (TIVO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01853644
Recruitment Status : Active, not recruiting
First Posted : May 15, 2013
Results First Posted : February 28, 2020
Last Update Posted : February 28, 2020
Sponsor:
Collaborator:
National Comprehensive Cancer Network
Information provided by (Responsible Party):
Daniela Matei, Northwestern University

Brief Summary:
This phase II trial studies how well tivozanib works in treating patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer. Tivozanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Condition or disease Intervention/treatment Phase
Recurrent Epithelial Ovarian Cancer Recurrent Fallopian Tube Cancer Recurrent Primary Peritoneal Cancer Drug: Tivozanib Phase 2

Detailed Description:

PRIMARY OBJECTIVES:

I. To determine the clinical activity of tivozanib in patients with platinum-resistant, recurrent ovarian, fallopian tube or primary peritoneal cancer.

SECONDARY OBJECTIVES:

I. Determining the potential survival advantage and characterizing the safety of single agent tivozanib in patients with platinum-resistant ovarian cancer.

OUTLINE:

Patients receive tivozanib hydrochloride orally (PO) once daily (QD) on days 1-21. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months for 3 years.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 31 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Efficacy and Safety of Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Actual Study Start Date : June 6, 2013
Actual Primary Completion Date : October 2, 2018
Estimated Study Completion Date : October 2023


Arm Intervention/treatment
Experimental: Treatment (Tivozanib)
Tivozanib 1.5mg orally given daily for 3 weeks with one week off to complete a 4 week cycle until disease progression or adverse effects prohibit further therapy
Drug: Tivozanib
1.5 mg Given PO (orally)days 1-21 or every 28 day cycle
Other Names:
  • AV-951
  • Oral VEGF receptor tyrosine kinase inhibitor AV-951




Primary Outcome Measures :
  1. Overall Response Rate (ORR) [ Time Frame: Time taken to reach first best response. Range 1-4 cycles (1 cycle = 28 days) ]

    ORR is defined as the percentage of patients with complete response plus those with partial response as measured by RECIST 1.1 where:

    Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.



Secondary Outcome Measures :
  1. Progression Free Survival (PFS) in Platinum-resistant Ovarian Cancer to Treatment With Single Agent Tivozanib [ Time Frame: Range of months 1-25 ]
    The Kaplan-Meier method will be utilized to estimate the median and overall distribution of PFS and will be defined from the start of treatment until the first documentation of progressive disease or death, whichever occurs first..

  2. Number of Adverse Events in Platinum-resistant Ovarian Cancer to Treatment With Single Agent Tivozanib [ Time Frame: During treatment and up to 30 days after completion of study treatment. Range of cycles 1-31 (1 cycle =28 days). ]
    Adverse events will be assessed by NCI CTCAE v 4.03. Adverse event that were determined to be serious adverse events (either grade 3, 4, or 5) related to study drug were collected. Grading is as follows:

  3. Overall Survival (OS) in Platinum-resistant Ovarian Cancer to Treatment With Single Agent Tivozanib [ Time Frame: Range of months 1-39 ]
    OS is defined from the start of treatment until date of death from any cause or date of last contact.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 110 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • • Patients must have recurrent or persistent, platinum resistant epithelial ovarian, fallopian tube or primary peritoneal carcinoma; platinum-resistant disease is defined as a recurrence within 6 months of completing adjuvant, platinum-based chemotherapy

    • Patients must have measurable disease or non-measurable (detectable) disease:

      • Measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded); each lesion must be greater than or equal to 10 mm when measured by computed tomography (CT), magnetic resonance imaging (MRI) or by clinical exam; or greater than or equal to 20 mm when measured by chest x-ray; lymph nodes must be greater than or equal to 15 mm in short axis when measured by CT or MRI
      • Non-measurable (detectable) disease in a patient is defined in this protocol as one who does not have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) criteria but does have a cancer antigen 125 (CA-125) greater than or equal to two times the upper normal limit within the last 60 days (confirmatory at baseline) and at least one of the following conditions:

        • Ascites and/or pleural effusion attributed to tumor
        • Hypermetabolic lesions on positron emission tomography (PET) scan
    • Patients with measurable disease must have at least one "target lesion" to be used to assess response on this protocol as defined by RECIST
    • Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
    • Recovery from effects of recent surgery, radiotherapy, or chemotherapy:

      • Patients should be free of active infection requiring antibiotics (with the exception of uncomplicated urinary tract infection [UTI])
      • Any other prior therapy directed at the malignant tumor, including chemotherapy, biological/targeted (non-cytotoxic) agents and immunologic agents, must be discontinued at least three weeks prior to registration
      • At least 4 weeks must have elapsed since the patient underwent any major surgery (e.g., major: laparotomy, laparoscopy, thoracotomy, video assisted thorascopic surgery (VATS); there is no restriction on minor procedures (e.g., minor: central venous access catheter placement, ureteral stent placement or exchange, paracentesis, thoracentesis)
    • Patients must have had one prior taxane and platinum-based chemotherapeutic regimen for management of primary disease containing carboplatin, cisplatin, or another organo platinum compound; this initial treatment may have included intraperitoneal therapy, consolidation, non-cytotoxic (biologic/targeted agents, such as bevacizumab) or extended therapy administered after surgical or non-surgical assessment; there is no maximum number of prior regimens;
    • patients may not have had any prior systemic therapy (including interleukin-2, interferon-alpha, chemotherapy, bevacizumab, investigational or licensed drug that targets vascular endothelial growth factor [VEGF] or VEGF receptors/pathway or are mammalian target of rapamycin [mTOR] inhibitors) for treatment of recurrent ovarian cancer
    • Patients must have signed an approved informed consent and authorization permitting the release of personal health information
    • Patients must meet pre-entry requirements
    • A female is eligible to participate if she is of non-childbearing potential or as documentation of a negative pregnancy test prior to the start of the study treatment; sexually active pre-menopausal female subjects must agree to use adequate, highly effective contraceptive measures, while on study and for 45 days after the last dose of last study drug; effective birth control includes (a) intrauterine device (IUD) plus one barrier method; (b) oral, implantable or injectable contraceptives plus one barrier method; or (c) 2 barrier methods; effective barrier methods are male or female condoms, diaphragms, and spermicides (creams or gels that contain a chemical to kill sperm)

Exclusion Criteria:

  • • Age < 18 years

    • Patients who have had previous treatment with tivozanib
    • Hemoglobin < 9.0 g/dL
    • Absolute neutrophil count (ANC) < 1500 per mm^3
    • Platelet count < 100,000 per mm^3
    • Total bilirubin > 1.5 × upper limit of normal (ULN) (or > 2.5 x ULN for subjects with asymptomatic Gilbert's syndrome)
    • Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2.5 × ULN (or > 5 × ULN for subjects with liver metastasis)
    • BOTH total bilirubin > ULN AND AST/ALT > ULN
    • Alkaline phosphatase > 2.5 × ULN (or > 5 × ULN for subjects with liver or bone metastasis)
    • Creatinine > 2.0 × ULN
    • Prothrombin time (PT) such that international normalized ratio (INR) > 1.5 x ULN (unless a patient is on therapeutic warfarin) or a partial thromboplastin time (PTT) > 1.5 x ULN
    • Proteinuria > 3+ by urinalysis or urine dipstick
    • Significant cardiovascular disease, including:

      • Symptomatic left ventricular dysfunction or baseline left ventricular ejection fraction (LVEF) by multigated acquisition scan (MUGA) or echocardiogram (ECHO) of =< lower limit of institutional normal (LLN)
      • Uncontrolled hypertension: systolic blood pressure of > 140 mmHg or diastolic blood pressure of > 90 mmHg documented on 2 consecutive measurements taken at least 24 hours apart
      • Myocardial infarction, severe angina, or unstable angina within 6 months prior to administration of first dose of study drug
      • History of serious ventricular arrhythmia (i.e., ventricular tachycardia or ventricular fibrillation)
      • Cardiac arrhythmias requiring anti-arrhythmic medications (except for atrial fibrillation that is well controlled with anti-arrhythmic medication)
      • Coronary or peripheral artery bypass graft within 6 months of screening
      • History of class III or IV congestive heart failure, as defined by the New York Heart Association
    • Central nervous system metastases; Note: subjects with previously treated (radiotherapy or surgery) brain metastasis that have been stable without steroid treatment for at least 3 months following prior treatment may be enrolled
    • Non-healing wound, bone fracture, or skin ulcer
    • Active peptic ulcer disease, inflammatory bowel disease, ulcerative colitis, or other gastrointestinal condition with increased risk of perforation; history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 4 weeks prior to administration of first dose of study drug
    • Serious/active infection or infection requiring parenteral antibiotics
    • Corrected QT interval (QTc) of > 480 msec using Bazett's formula
    • Radiotherapy or minor surgical procedure within 2 weeks, or major surgical procedure within 4 weeks prior to administration of first dose of study drug; inadequate recovery from prior surgical procedure
    • Significant thromboembolic or vascular disorders within 6 months prior to administration of first dose of study drug, including but not limited to:

      • Deep vein thrombosis
      • Pulmonary embolism
      • Cerebrovascular accident (CVA) or transient ischemic attack (TIA)
      • Peripheral arterial ischemia > grade 2 (per National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] version 4.0)
    • Significant bleeding disorders within 6 months prior to administration of first dose of study drug, including but not limited to:

      • Hematemesis, hematochezia, melena or other gastrointestinal bleeding >= grade 2 (per CTCAE version 4.0)
      • Hemoptysis or other pulmonary bleeding >= grade 2 (per CTCAE Version 4.0)
      • Hematuria or other genitourinary bleeding >= grade 2 (per CTCAE Version 4.0)
    • Currently active second primary malignancy, including hematologic malignancies (leukemia, lymphoma, multiple myeloma, etc.), other than non-melanoma skin cancers, non-metastatic prostate cancer, in situ cervical cancer, and ductal or lobular carcinoma in situ of the breast; subjects are considered to have a currently active malignancy if they have completed anti-cancer therapy and have not been disease free for > 2 years
    • Pregnant or lactating females
    • History of genetic or acquired immune suppression disease such as human immunodeficiency virus (HIV); subjects on immune suppressive therapy for organ transplant
    • Life-threatening illness or organ system dysfunction compromising safety evaluation
    • Requirement for hemodialysis or peritoneal dialysis
    • Inability to swallow capsules, malabsorption syndrome or gastrointestinal disease that severely affects the absorption of study drugs, major resection of the stomach or small bowel, or gastric bypass procedure
    • Known hypersensitivity to drugs chemically related to tivozanib hydrochloride or sunitinib or their excipients
    • Psychiatric disorder or altered mental status precluding informed consent or protocol-related testing

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01853644


Locations
Layout table for location information
United States, Illinois
Northwestern University
Chicago, Illinois, United States, 60611
CDH-Delnor Health System - Northwestern Medicine Cancer Center
Warrenville, Illinois, United States, 60555
Sponsors and Collaborators
Northwestern University
National Comprehensive Cancer Network
Investigators
Layout table for investigator information
Principal Investigator: Daniela Matei, MD Northwestern University
  Study Documents (Full-Text)

Documents provided by Daniela Matei, Northwestern University:
Layout table for additonal information
Responsible Party: Daniela Matei, Daniela Matei, MD, Northwestern University
ClinicalTrials.gov Identifier: NCT01853644    
Other Study ID Numbers: STU00073756
First Posted: May 15, 2013    Key Record Dates
Results First Posted: February 28, 2020
Last Update Posted: February 28, 2020
Last Verified: February 2020
Keywords provided by Daniela Matei, Northwestern University:
Cancer
Recurrent
Ovary
Fallopian Tube
Primary Peritioneal
Phase II
Platinum Resistant
Additional relevant MeSH terms:
Layout table for MeSH terms
Fallopian Tube Neoplasms
Peritoneal Neoplasms
Carcinoma, Ovarian Epithelial
Ovarian Neoplasms
Endocrine Gland Neoplasms
Neoplasms by Site
Neoplasms
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders
Fallopian Tube Diseases
Abdominal Neoplasms
Digestive System Neoplasms
Digestive System Diseases
Peritoneal Diseases
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type